ProCE Banner Activity

CME

Think You Know NASH? A Quiz-Based Challenge on Current and Emerging Management Strategies

In this on-demand Webcast, expert faculty review the science of NASH, available diagnostic resources and management strategies, and the latest emerging and investigational therapies.

Physicians : maximum of 1.75 AMA PRA Category 1 {Credits}

Released: November 20, 2017

Expiration: November 19, 2018

No longer available for credit.

Share

Faculty

Quentin M. Anstee

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP

Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Stephen A. Harrison

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Rohit Loomba

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Target Audience

This program is intended for hepatologists, gastroenterologists, and other healthcare providers who care for patients with or at risk for NASH.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider key risk factors for development of NAFLD and the pathophysiologic mechanisms that lead to NASH
  • Identify patients at risk for NASH and employ appropriate testing strategies to confirm diagnosis
  • Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, safety data, and their potential utility in the treatment of patients with NASH

Faculty Disclosure

Primary Author

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP

Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Abbott, Acuitas Medical, Allergan/Tobira, E3Bio, Galmed, Genfit, Gilead Sciences, Grünenthal, Imperial Innovations, Intercept Pharma Europe Ltd, Inventiva, Janssen, Lilly, MedImmune, NewGen, Novartis, Pfizer, and Raptor Pharma; funds for research support paid to his institution from AbbVie, Allergan/Tobira, AstraZeneca, GlaxoSmithKline, Novartis, and Vertex; active research collaborations (including the EU H2020 EPoS & EU IMI2 LITMUS Consortia*) AbbVie, Antaros Medical,* Allergan/Tobira, AstraZeneca, Boehringer Ingelheim,* Ellegaard Göttingen Minipigs AS,* Exalenz Bioscience,* Genfit,* GlaxoSmithKline, Intercept Pharma Europe,* iXscient,* Lilly,* Nordic Bioscience,* Novartis,* Novo Nordisk A/S,* One Way Liver Genomics SL,* Perspectum Diagnostics,* Pfizer,* sanofi-aventis Deutschland,* SomaLogic,* and Takeda Pharmaceuticals International*; and speaking fees from Abbott, Allergan/Tobira, Falk, Genfit, Gilead Sciences, and Intercept Pharma.

Stephen A. Harrison, MD, MAJ (P), MC

Chief of Hepatology
Division of Gastroenterology and Hepatology
Brooke Army Medical Center
Fort Sam Houston, Texas

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Capulus, Cirius, Genfit, Echosens, Histoindex, Intercept, Madrigal, NGM Bio, and Perspectum; has received fees for non-CME/CE services from AbbVie, Alexion, and Gilead Sciences; and has an ownership interest in Cirius.

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Rohit Loomba, MD, MHSc, has disclosed that he has received consulting fees from Alnylam, Arrowhead, Galmed, Gilead Sciences, Janssen, Tobira, and Zafgen; has received funds for research support from Daiichi Sankyo, Galectin, Galmed, Gilead Sciences, Immuron, Merck, and Promedior; and has ownership interest in and a receipt of intellectual property rights/patent holder relationship with Liponexus.

Staff Disclosure

Staff

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 20, 2017, through November 19, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in identifying and managing patients with NASH.